November 10, 2025

To Whom It May Concern

Company Name: Sawai Group Holdings Co., Ltd.
Representative: Mitsuo Sawai
President and Representative Director
(Securities Code: 4887 Prime Market of Tokyo Stock Exchange)
Contact: Yasushi Kora
Deputy General Manager
Group Finance Department
(Telephone Number: +81-6-6105-5823)

Notice Regarding Recognition of Other Expenses (Provision for Loss on Litigation)

Sawai Group Holdings Co., Ltd. (hereinafter the "Company") published the "Notice Regarding Settlement of Lawsuit" dated October 21, 2025. In connection with this, the Company hereby announces that it has decided to recognize a provision for loss on litigation in the financial results for the second quarter (interim period) ended September 30, 2025, of the fiscal year ending March 31, 2026.

1. Recognition of provision for loss on litigation

   Sawai Pharmaceutical Co., Ltd., a consolidated subsidiary of the Company, reached a settlement concerning the patent infringement lawsuit of Teriparatide Subcutaneous Injection 56.5μg [Sawai], as stated in the "Notice Regarding Settlement of Lawsuit" dated October 21, 2025. Therefore, the Company decided to recognize the provision for litigation loss related to the settlement amounting to 4 billion yen as other expense in the second quarter (interim period) ended September 30, 2025, of the fiscal year ended March 31, 2026.

2. Impact on Financial Results

   Provision for loss on litigation amounting to 4 billion yen will be recognized as other expense for the second quarter (interim period) ended September 30, 2025, of the fiscal year ended March 31, 2026.

   The interim dividend amount for the fiscal year ended March 31, 2026 (27 yen per share) and the year-end dividend amount for the fiscal year ending March 31, 2026 (28 yen per share), originally announced on May 14, 2025, remain unchanged.